{
    "eid": "2-s2.0-85008395149",
    "title": "Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial",
    "cover-date": "2017-01-03",
    "subject-areas": [
        {
            "$": "General Medicine",
            "@code": "2700"
        }
    ],
    "keywords": [],
    "authors": [
        "Hope S. Rugo"
    ],
    "citedby-count": 130,
    "ref-count": 25,
    "ref-list": [
        "Targeted therapy of cancer: New prospects for antibodies and immunoconjugates",
        "Monoclonal antibodies in gynecological cancer: A critical point of view",
        "Barriers to the access and use of rituximab in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia: A physician survey",
        "Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the united states and emerging markets",
        "Worldwide experience with biosimilar development",
        "A clinician's guide to biosimilars in oncology",
        "Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 - Positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831",
        "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer",
        "Adjuvant trastuzumab in HER2-positive breast cancer.",
        "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial",
        "Pharmacology 2015 Meeting of the British Pharmacological Society",
        "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)",
        "Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer",
        "Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2",
        "Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group",
        "Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer",
        "The economic implications of biosimilars",
        "The Cost Savings Potential of Biosimilar Drugs in the United States",
        "Guideline on Similar Biological Medicinal Products",
        "Scientific Considerations in Demonstrating Biosimilarity to A Reference Product: Guidance for Industry",
        "Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)",
        "Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results of NCIC CTG MA.31",
        "J Clin Oncol",
        "Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): A phase 3, open-label, multicentre, randomised trial",
        "ESMO Congress 2012 of the European Society for Medical Oncology"
    ],
    "affiliation": [
        {
            "affiliation-city": "Canonsburg",
            "affilname": "Mylan Inc.",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Dnipro",
            "affilname": "Dnipro State Medical University",
            "affiliation-country": "Ukraine"
        },
        {
            "affiliation-city": "San Francisco",
            "affilname": "UCSF Helen Diller Family Comprehensive Cancer Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Freiburg im Breisgau",
            "affilname": "Universit\u00e4tsklinikum Freiburg",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Sumy",
            "affilname": "Sumy State University",
            "affiliation-country": "Ukraine"
        },
        {
            "affiliation-city": "Baltimore",
            "affilname": "Johns Hopkins Bloomberg School of Public Health",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Manila",
            "affilname": "Cardinal Santos Medical Center",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Bengaluru",
            "affilname": "Biocon Research Limited",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Tbilisi",
            "affilname": "Golden Fleece 21 Century Health House Ltd",
            "affiliation-country": "Georgia"
        },
        {
            "affiliation-city": "Vijayawada",
            "affilname": "City Cancer Center",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Barcelona",
            "affilname": "Quiron-Dexeus",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Nasik",
            "affilname": "HCG Manavata Cancer Centre",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Kazan",
            "affilname": "Regional Clinical Oncological Center",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Taguig",
            "affilname": "St. Luke's Medical Center Global City",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Saint Petersburg (ex Leningrad)",
            "affilname": "City Clinical Oncology Dispensary",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Temuco",
            "affilname": "Instituto Clinico Oncologico del Sur",
            "affiliation-country": "Chile"
        },
        {
            "affiliation-city": "Tbilisi",
            "affilname": "Institute of Clinical Oncology",
            "affiliation-country": "Georgia"
        }
    ],
    "funding": []
}